Technology | Mammography | December 11, 2017

Siemens Healthineers Introduces Mammomat Revelation Mammography System for Improved Biopsy Workflow

3D HD Breast Biopsy uses company’s 50-degree wide-angle HD breast tomosynthesis to obtain more targeted, accurate biopsies at a lower dose; system also offers automated breast density measurement and titanium contrast-enhanced mammography exams

Siemens Healthineers Introduces Mammomat Revelation Mammography System for Improved Biopsy Workflow

December 11, 2017 — Siemens Healthineers unveiled the new Mammomat Revelation premium mammography platform at the 2017 Radiological Society of North America (RSNA) Annual Meeting, Nov. 26-Dec. 1 in Chicago. Mammomat Revelation enables healthcare providers to expand precision medicine, improve clinical outcomes and increase patient satisfaction, according to the company. The system’s HD Breast Biopsy solution enables one-click targeting of suspicious areas with a +/- 1mm accuracy. The new integrated specimen imaging tool facilitates immediate control of the biopsy directly at the mammography system. Clinical workflow is improved by eliminating the need for a second imaging system and by reducing patient compression time. Mammomat Revelation also provides automated breast density measurements at the point of care. Additionally, it expands existing diagnostic options and provides patient access to functional breast imaging with contrast-enhanced mammography.

With its 50-degree 3-D HD Breast Tomosynthesis, Siemens Healthineers said the system offers the widest scan angle available. This scan angle is the basis for what it calls the industry’s highest depth resolution, which provides extremely high-quality 3-D images to increase diagnostic confidence and enable earlier detection of even subtle lesions. With Mammomat Revelation, the clinician also can perform biopsies based on 3-D HD Breast Tomosynthesis. The HD Breast Biopsy solution enables one-click targeting of suspicious areas with a +/- 1mm accuracy.

Upon acquisition, the tissue sample must be X-rayed to confirm a successful biopsy. In clinical practice today, samples are usually imaged on a second system or on a dedicated specimen scanner, usually in a different room. During this time, the patient remains under compression. Mammomat Revelation can substantially reduce discomfort and anxiety with the InSpect integrated specimen imaging tool. Biopsy samples can be imaged and visualized at the technologist workstation within 20 seconds without radiation exposure to the patient. The system improves the biopsy workflow, shortens patient compression time and improves the patient experience.

In addition, Mammomat Revelation is the industry’s first mammography platform to provide automated breast density measurements at the point of examination, according to Siemens. Currently, radiologists must estimate breast density visually during the image reading process, which typically occurs after the patient has left the facility. Patients with high breast density at higher risk of developing breast cancer often require additional workup to rule out breast cancer. Additional imaging procedures require patient callbacks, which can lead to uncertainty and concern. The information provided by Mammomat Revelation not only enables immediate, personalized risk stratification, but it also allows the facility to provide supplemental imaging while the patient is at the facility. Patients receive results faster, minimizing patient uncertainty and stress.

In some cases, purely morphological information from a mammogram or tomosynthesis scan may be insufficient for a precise diagnosis. For example, distinguishing scar tissue from new lesions in a post-surgical examination can be difficult. In addition to purely morphological information, clinicians may require functional information that can be obtained through contrast-enhanced imaging, which is usually performed using breast magnetic resonance imaging (MRI). Mammomat Revelation enables functional imaging directly on the mammography system. Since mammography systems are more widely available than MRI scanners, patient access to more specific breast imaging tools can be improved. And since contrast-enhanced mammography is still not widely utilized, the modular arrangement of the new system enables its expansion to include this and other functionality on an as-needed basis.

Finally, discomfort and pain in addition to related anxiety are key reasons why patients avoid mammography exams. With Mammomat Revelation’s Personalized Soft Compression, the breast compression process is softened and the compression force is automatically and individually adjusted. Coupled with ergonomic SoftComp Paddles, Personalized Soft Compression enables better breast positioning, more consistent image quality, and reduced patient discomfort.

Mammomat Revelation and Insight BD are U.S. Food and Drug Administration (FDA) 510(k)-pending and are not commercially available in the United States.

For more information: www.usa.healthcare.siemens.com

Related Content

Recognized as the “Pulitzer Prize of the business press,” the Jesse H. Neal Award finalists are selected for exhibiting journalistic enterprise, service to the industry and editorial craftsmanship
News | Radiology Business | February 19, 2020
February 19, 2020 — Connectiv, a division of The Software and Information Industry Association (SIIA), has announced
Mammograms of a 49-year-old woman with invasive lobular carcinoma on the right-side breast

Mammograms of a 49-year-old woman with invasive lobular carcinoma on the right-side breast. A small mass with micro-calcifications on the right-side breast was detected correctly by AI with an abnormality score of 96%. This case was recalled by 7 out of 14 radiologists (4 breast radiologists and 3 general radiologists) initially (without AI) and all 14 radiologists recalled this case correctly with the assistance of AI.

News | Artificial Intelligence | February 11, 2020
February 11, 2020 — A new study, published in...
Sponsored Content | Videos | Artificial Intelligence | February 06, 2020
ProFound AI is an FDA-cleared artificial intelligence (AI) system for reading 3-D breast tomosynthesis images.
Feature | Breast Imaging | February 03, 2020 | By Barbara Smith
Women in the United States have a 1 in 8 (or about 13 percent) lifetime risk of being diagnosed with breast cancer du
ringing the cancer bell can do more harm than good, says an ASTRO study

Image courtesy of ASTRO

News | Radiation Oncology | January 27, 2020
January 27, 2020 — It's a scene that some cancer patients dream about: they celebrate the end of a course of radiatio
A 50-y-old postmenopausal woman with fibroadenoma (arrows) in left breast

A 50-y-old postmenopausal woman with fibroadenoma (arrows) in left breast. (A) Unenhanced fat-saturated T1-weighted MRI shows extreme amount of FGT (ACR d). (B) Moderate BPE is seen on dynamic contrast-enhanced MRI at 90 s. (C) Mean ADC of breast parenchyma of contralateral breast on diffusion-weighted imaging with ADC mapping is 1.5 × 10?3 mm2/s. (D) On 18F-FDG PET/CT, lesion is not 18F-FDG-avid, and BPU of normal breast parenchyma is relatively high, with SUVmax of 3.2. Photo courtesy of K Pinker, et al., Medical University of Vienna, Vienna, Austria

News | PET-MRI | January 27, 2020
January 27, 2020 — Researchers have identified several potentially useful...
Sponsored Content | Videos | Mammography | January 24, 2020
Imaging Technology News Contributing Editor Greg Freiherr interviewed...
Virtual reality during chemotherapy has been shown to improve breast cancer patients’ quality of life during the most stressful treatments
News | Virtual and Augmented Reality | January 21, 2020
January 21, 2020 — Virtual reality during chemotherapy has been shown to improve...